Cleared Traditional

BPCARD (K031964) - FDA 510(k) Clearance

Class II Cardiovascular device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K031964 · Qrs Diagnostic, LLC · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 2003
Decision
72d
Days
Class 2
Risk

K031964 is an FDA 510(k) clearance for the BPCARD. Classified as System, Measurement, Blood-pressure, Non-invasive (product code DXN), Class II - Special Controls.

Submitted by Qrs Diagnostic, LLC (Plymouth, US). The FDA issued a Cleared decision on September 5, 2003 after a review of 72 days - a notably fast clearance cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1130 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Qrs Diagnostic, LLC devices

Submission Details

510(k) Number K031964 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 25, 2003
Decision Date September 05, 2003
Days to Decision 72 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
53d faster than avg
Panel avg: 125d · This submission: 72d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DXN System, Measurement, Blood-pressure, Non-invasive
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1130
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - DXN System, Measurement, Blood-pressure, Non-invasive

All 286
Devices cleared under the same product code (DXN) and FDA review panel - the closest regulatory comparables to K031964.
DEVICE CONNECTIVITY SOFTWARE DEVELOPERS KIT (SDK), MODEL 4500-900
K052784 · Welch Allyn, Inc. · Nov 2005
CLEVER TD-3018A BLOOD PRESSURE MONITOR
K051703 · Taidoc Technology Corporation · Aug 2005
WELCH ALLYN SPOT ULTRA VITAL SIGNS DEVICE
K040490 · Welch Allyn, Inc. · Aug 2004
WELCH ALLYN VITAL SIGN MONITOR WITH MP506
K024005 · Welch Allyn, Inc. · Feb 2003
WELCH ALLYN VITALS SOFTWARE DEVELOPERS KIT (SDK)
K023495 · Welch Allyn, Inc. · Oct 2002
WELCH ALLYN ABPM 6100
K021756 · Welch Allyn, Inc. · Jun 2002